<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00786448</url>
  </required_header>
  <id_info>
    <org_study_id>12245</org_study_id>
    <secondary_id>EX0501DE</secondary_id>
    <nct_id>NCT00786448</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance Study on Emselex After Launch in Germany</brief_title>
  <official_title>Post-Marketing Surveillance Study Emselex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      - Data are obtained of Emselex in routine treatment of Overactive Bladder. The general
      objectives are to evaluate the product safety, compatibility, efficacy and patient
      acceptance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, Adverse drug reactions, physician's global assessment of tolerability</measure>
    <time_frame>After 2-3 months of treatment (long-term 6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incontinence</measure>
    <time_frame>At end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgency episodes</measure>
    <time_frame>At end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micturitions / nycturitions</measure>
    <time_frame>At end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's assessment of improvement/efficacy</measure>
    <time_frame>At end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's assessment of patient's satisfaction with therapeutic effect</measure>
    <time_frame>At end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's assessment of patient's ability to hold urine</measure>
    <time_frame>At end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose and treatment duration of Emselex</measure>
    <time_frame>At end of study</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5821</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin, Emselex (BAY79-4998)</intervention_name>
    <description>Patients from routine practice</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from routine practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are treated with Emselex for Overactive Bladder

        Exclusion Criteria:

          -  Exclusion criteria are the contraindications as specified in the German product
             information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2008</study_first_submitted>
  <study_first_submitted_qc>November 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2008</study_first_posted>
  <last_update_submitted>April 29, 2010</last_update_submitted>
  <last_update_submitted_qc>April 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Bayer Schering Pharma AG</organization>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darifenacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

